Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Electrographic flow-guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale

T. Szili-Torok, P. Neuzil, A. Langbein, J. Petru, M. Funasako, L. Dinshaw, S. Wijchers, R. Bhagwandien, A. Rillig, SG. Spitzer, A. Metzner, MH. Kong, VY. Reddy

. 2023 ; 4 (6) : 391-400. [pub] 20230423

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23009622

BACKGROUND: Electrographic flow (EGF) mapping enables the dynamic detection of functional or active atrial fibrillation (AF) sources outside the pulmonary veins (PVs), and the presence or absence of these sources offers a novel framework for classifying and treating persistent AF patients based on the underlying pathophysiology of their AF disease. OBJECTIVE: The primary objective of the FLOW-AF trial is to evaluate the reliability of the EGF algorithm technology (Ablamap software) to identify AF sources and guide ablation therapy in patients with persistent AF. METHODS: The FLOW-AF trial (NCT04473963) is a prospective, multicenter, randomized clinical study in which patients with persistent or long-standing persistent AF who have failed prior PV isolation (PVI) undergo EGF mapping after confirmation of intact PVI. In total, 85 patients will be enrolled and stratified based on the presence or absence of EGF-identified sources. Patients with an EGF-identified source above the predetermined activity threshold of ≥26.5% will be randomized in a 1:1 fashion to PVI only vs PVI + ablation of EGF-identified extra-PV sources of AF. RESULTS: The primary safety endpoint is freedom from serious adverse events related to the procedure through 7 days following the randomization procedure; and the primary effectiveness endpoint is the successful elimination of significant sources of excitation with the target parameter the activity of the leading source. CONCLUSIONS: The FLOW-AF trial is a randomized study designed to evaluate the ability of the EGF mapping algorithm to identify patients with active extra-PV AF sources.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23009622
003      
CZ-PrNML
005      
20230721095526.0
007      
ta
008      
230707s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.hroo.2023.04.001 $2 doi
035    __
$a (PubMed)37361617
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Szili-Torok, Tamas $u Department of Cardiology, Erasmus MC, Rotterdam, the Netherlands
245    10
$a Electrographic flow-guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale / $c T. Szili-Torok, P. Neuzil, A. Langbein, J. Petru, M. Funasako, L. Dinshaw, S. Wijchers, R. Bhagwandien, A. Rillig, SG. Spitzer, A. Metzner, MH. Kong, VY. Reddy
520    9_
$a BACKGROUND: Electrographic flow (EGF) mapping enables the dynamic detection of functional or active atrial fibrillation (AF) sources outside the pulmonary veins (PVs), and the presence or absence of these sources offers a novel framework for classifying and treating persistent AF patients based on the underlying pathophysiology of their AF disease. OBJECTIVE: The primary objective of the FLOW-AF trial is to evaluate the reliability of the EGF algorithm technology (Ablamap software) to identify AF sources and guide ablation therapy in patients with persistent AF. METHODS: The FLOW-AF trial (NCT04473963) is a prospective, multicenter, randomized clinical study in which patients with persistent or long-standing persistent AF who have failed prior PV isolation (PVI) undergo EGF mapping after confirmation of intact PVI. In total, 85 patients will be enrolled and stratified based on the presence or absence of EGF-identified sources. Patients with an EGF-identified source above the predetermined activity threshold of ≥26.5% will be randomized in a 1:1 fashion to PVI only vs PVI + ablation of EGF-identified extra-PV sources of AF. RESULTS: The primary safety endpoint is freedom from serious adverse events related to the procedure through 7 days following the randomization procedure; and the primary effectiveness endpoint is the successful elimination of significant sources of excitation with the target parameter the activity of the leading source. CONCLUSIONS: The FLOW-AF trial is a randomized study designed to evaluate the ability of the EGF mapping algorithm to identify patients with active extra-PV AF sources.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Neuzil, Petr $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic
700    1_
$a Langbein, Anke $u Department of Cardiology, Praxisklinik Herz und Gefaesse, Dresden, Germany
700    1_
$a Petru, Jan $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic
700    1_
$a Funasako, Moritoshi $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic
700    1_
$a Dinshaw, Leon $u Department of Cardiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Wijchers, Sip $u Department of Cardiology, Erasmus MC, Rotterdam, the Netherlands
700    1_
$a Bhagwandien, Rohit $u Department of Cardiology, Erasmus MC, Rotterdam, the Netherlands
700    1_
$a Rillig, Andreas $u Department of Cardiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Spitzer, Stefan G $u Department of Cardiology, Praxisklinik Herz und Gefaesse, Dresden, Germany
700    1_
$a Metzner, Andreas $u Department of Cardiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Kong, Melissa H $u Ablacon, Inc, Wheat Ridge, Colorado
700    1_
$a Reddy, Vivek Y $u Department of Cardiology, Homolka Hospital, Prague, Czech Republic $u Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York
773    0_
$w MED00209104 $t Heart rhythm O2 $x 2666-5018 $g Roč. 4, č. 6 (2023), s. 391-400
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37361617 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20230721095520 $b ABA008
999    __
$a ok $b bmc $g 1958433 $s 1195886
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 4 $c 6 $d 391-400 $e 20230423 $i 2666-5018 $m Heart rhythm O2 $n Heart Rhythm O2 $x MED00209104
LZP    __
$a Pubmed-20230707

Najít záznam

Citační ukazatele

Možnosti archivace